Thursday, January 6, 2011

Regeneron Pharma (NASDAQ:REGN) Has Strong Short and Long Term Catalysts

Regeneron Pharma (NASDAQ:REGN) looks like they're positioned well for short- and long-term growth, with a mixture of products adding to the overall success of the company.

Needham noted, "In the near-term, we believe the data presentations and submissions for VEGF Trap-Eye in AMD and Phase 3 RILONACEPT data in gout prevention will provide significant catalysts to the stock. In the long-term, we believe data from the oncology program, progress of early stage mAb programs, and the evergreen technology platform will serve to drive the long-term growth of the Company."

Needham & Company reiterates a "Buy" on Regeneron Pharma, which closed Wednesday at $33.29, up $0.03, or 0.11 percent. Needham has a price target of $39 on them.

No comments: